Edgewise Therapeutics (EWTX) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $37.19, -2.64% vs the prior close of $38.20.
- Volume 1.14M shares, 0.8x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
EWTX dips 2.6% to $37.19. Closed at $37.19, -2.64% vs the prior close of $38.20. Day range $36.70β$38.28, opened at $38.28.
EWTX daily analysis β what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 β EWTX dips 2.6% to $37.19
- Closed at $37.19, -2.64% vs the prior close of $38.20. Day range $36.70β$38.28, opened at $38.28.
- Volume was 1.14M shares, 0.8x its 50-day average of 1.43M.
- Price is -12.1% vs its 50-day average ($42.29) and +4.6% vs its 200-day average ($35.54).
- 52-week range $14.68β$48.51; today's close sits at 67% of that range, 23.3% below the 52-week high.
Oct 15, 2026 β EWTX jumps 3.2% to $38.20
- Closed at $38.20, +3.19% vs the prior close of $37.02. Day range $37.24β$38.53, opened at $37.62.
- Volume was 1.84M shares, 1.3x its 50-day average of 1.43M.
- Price is -10.0% vs its 50-day average ($42.44) and +7.7% vs its 200-day average ($35.48).
- 52-week range $14.68β$48.51; today's close sits at 70% of that range, 21.3% below the 52-week high.
Oct 14, 2026 β EWTX rises 2.0% to $37.02
- Closed at $37.02, +2.04% vs the prior close of $36.28. Day range $35.63β$37.94, opened at $35.93.
- Volume was 1.45M shares, 1.0x its 50-day average of 1.49M.
- Price is -13.0% vs its 50-day average ($42.57) and +4.5% vs its 200-day average ($35.41).
- 52-week range $14.25β$48.51; today's close sits at 66% of that range, 23.7% below the 52-week high.
Oct 13, 2026 β EWTX slides 5.6% to $36.28, a 3-month low, 7 down days in a row
- Closed at $36.28, -5.64% vs the prior close of $38.45. Day range $36.08β$38.35, opened at $38.17.
- Volume was 810.10K shares, 0.5x its 50-day average of 1.49M β lighter than usual.
- Price is -15.1% vs its 50-day average ($42.73) and +2.6% vs its 200-day average ($35.36).
- 52-week range $14.25β$48.51; today's close sits at 64% of that range, 25.2% below the 52-week high.
- That makes 7 straight losses.
Oct 12, 2026 β EWTX dips 1.6% to $38.45, a 1-month low, 6 down days in a row
- Closed at $38.45, -1.56% vs the prior close of $39.06. Day range $38.32β$39.36, opened at $39.12.
- Volume was 1.54M shares, 1.0x its 50-day average of 1.48M.
- Price is -10.1% vs its 50-day average ($42.77) and +8.9% vs its 200-day average ($35.31).
- 52-week range $14.25β$48.51; today's close sits at 71% of that range, 20.7% below the 52-week high.
- That makes 6 straight losses.
Oct 9, 2026 β EWTX dips 0.4% to $39.06, a 1-month low, 5 down days in a row
- Closed at $39.06, -0.43% vs the prior close of $39.23. Day range $38.93β$40.41, opened at $39.30.
- Volume was 1.06M shares, 0.7x its 50-day average of 1.47M.
- Price is -8.7% vs its 50-day average ($42.77) and +10.9% vs its 200-day average ($35.23).
- 52-week range $14.25β$48.51; today's close sits at 72% of that range, 19.5% below the 52-week high.
- That makes 5 straight losses.
Oct 8, 2026 β EWTX dips 0.9% to $39.23, 4 down days in a row
- Closed at $39.23, -0.86% vs the prior close of $39.57. Day range $37.24β$39.41, opened at $38.14.
- Volume was 1.36M shares, 0.9x its 50-day average of 1.46M.
- Price is -8.4% vs its 50-day average ($42.81) and +11.6% vs its 200-day average ($35.14).
- 52-week range $14.25β$48.51; today's close sits at 73% of that range, 19.1% below the 52-week high.
- That makes 4 straight losses.
Oct 7, 2026 β EWTX dips 1.1% to $39.57, 3 down days in a row
- Closed at $39.57, -1.12% vs the prior close of $40.02. Day range $39.40β$41.06, opened at $39.66.
- Volume was 1.45M shares, 1.0x its 50-day average of 1.45M.
- Price is -7.6% vs its 50-day average ($42.82) and +12.8% vs its 200-day average ($35.07).
- 52-week range $14.25β$48.51; today's close sits at 74% of that range, 18.4% below the 52-week high.
- That makes 3 straight losses.
Oct 6, 2026 β EWTX dips 0.7% to $40.02
- Closed at $40.02, -0.69% vs the prior close of $40.30. Day range $39.34β$41.03, opened at $40.66.
- Volume was 1.62M shares, 1.1x its 50-day average of 1.44M.
- Price is -6.6% vs its 50-day average ($42.83) and +14.4% vs its 200-day average ($34.98).
- 52-week range $14.25β$48.51; today's close sits at 75% of that range, 17.5% below the 52-week high.
Oct 5, 2026 β EWTX dips 2.7% to $40.30
- Closed at $40.30, -2.66% vs the prior close of $41.40. Day range $39.98β$41.79, opened at $41.55.
- Volume was 1.63M shares, 1.1x its 50-day average of 1.43M.
- Price is -6.0% vs its 50-day average ($42.87) and +15.5% vs its 200-day average ($34.89).
- 52-week range $14.25β$48.51; today's close sits at 76% of that range, 16.9% below the 52-week high.
Oct 2, 2026 β EWTX rises 2.3% to $41.40
- Closed at $41.40, +2.27% vs the prior close of $40.48. Day range $40.42β$41.94, opened at $41.01.
- Volume was 1.46M shares, 1.0x its 50-day average of 1.42M.
- Price is -3.4% vs its 50-day average ($42.88) and +19.0% vs its 200-day average ($34.80).
- 52-week range $14.25β$48.51; today's close sits at 79% of that range, 14.7% below the 52-week high.
EWTX latest news & SEC filings
Every SEC filing by or about EWTX in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 2, 2026 Β· Form 4 β Insider trade
Insider trade report (Form 4) β a director, officer or 10%+ owner changed their holdings
- Fox Jonathan C received an award of 308 shares on Oct 1, 2026; now holds 25,141
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 17, 2026 Β· Form 4/A β Insider trade (amended)
Amended insider trade report (Form 4/A)
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 17, 2026 Β· Form 4/A β Insider trade (amended)
Amended insider trade report (Form 4/A)
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 17, 2026 Β· Form 4/A β Insider trade (amended)
Amended insider trade report (Form 4/A)
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 17, 2026 Β· Form 4/A β Insider trade (amended)
Amended insider trade report (Form 4/A)
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 17, 2026 Β· Form 4/A β Insider trade (amended)
Amended insider trade report (Form 4/A)
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 14, 2026 Β· Form SCHEDULE 13G/A β Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 Β· Form SCHEDULE 13G/A β Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 Β· Form SCHEDULE 13G/A β Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 Β· Form SCHEDULE 13G β Passive stake (13G)
Passive stake (13G) β an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 Β· Form 10-Q β Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$57.33M (prior year -$36.12M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.53 (prior year -$0.34) (loss widened vs Jun 30, 2025)
Aug 6, 2026 Β· Form 8-K β Major event / current report
Current report β a filing companies must make within 4 business days of a major event
- Item 2.02 β Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 16, 2026 Β· Form 8-K/A β Current report (amended)
Amended current report
- Exhibits / financial statements only (Item 9.01).
Jul 13, 2026 Β· Form 8-K β Major event / current report
Current report β a filing companies must make within 4 business days of a major event
- Item 2.01 β Completed an acquisition or sale of assets.
- Item 7.01 β Released information under Regulation FD (e.g. a presentation or press release).
Things to know before you trade EWTX
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Feb 26, 2026, Nov 6, 2025. Based on that rhythm, the next report is likely around Nov 5, 2026 β an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 2.20% (largest 7.8%).
- Liquidity: about 1.65M shares (β$61.32M) trade per day on average.
- 52-week position: $37.19 vs a range of $14.68β$48.51 (67% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Joanne M. Donovan sold 2,919 shares on Aug 13, 2026.
- Latest filings: 10-Q Aug 6, 2026; 8-K Aug 6, 2026; 8-K Jul 13, 2026.
- Share count: 108.60M shares outstanding (Jul 31, 2026), +3.1% vs a year earlier.
- Listing: Nasdaq Β· industry: Pharmaceutical Preparations.
EWTX market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 38.28 | 38.28 | 36.70 | 37.19 | 1.14M |
| Oct 15, 2026 | 37.62 | 38.53 | 37.24 | 38.20 | 1.84M |
| Oct 14, 2026 | 35.93 | 37.94 | 35.63 | 37.02 | 1.45M |
| Oct 13, 2026 | 38.17 | 38.35 | 36.08 | 36.28 | 810.10K |
| Oct 12, 2026 | 39.12 | 39.36 | 38.32 | 38.45 | 1.54M |
| Oct 9, 2026 | 39.30 | 40.41 | 38.93 | 39.06 | 1.06M |
| Oct 8, 2026 | 38.14 | 39.41 | 37.24 | 39.23 | 1.36M |
| Oct 7, 2026 | 39.66 | 41.06 | 39.40 | 39.57 | 1.45M |
| Oct 6, 2026 | 40.66 | 41.03 | 39.34 | 40.02 | 1.62M |
| Oct 5, 2026 | 41.55 | 41.79 | 39.98 | 40.30 | 1.63M |
| Oct 2, 2026 | 41.01 | 41.94 | 40.42 | 41.40 | 1.46M |
| Oct 1, 2026 | 40.39 | 41.46 | 39.86 | 40.48 | 1.29M |
| Sep 30, 2026 | 39.49 | 42.12 | 38.89 | 40.60 | 1.68M |
| Sep 29, 2026 | 39.53 | 39.58 | 38.51 | 39.19 | 1.92M |
| Sep 28, 2026 | 39.12 | 40.10 | 39.12 | 39.79 | 2.98M |
| Sep 25, 2026 | 41.59 | 41.99 | 38.57 | 39.34 | 2.49M |
| Sep 24, 2026 | 40.28 | 41.94 | 39.74 | 41.16 | 1.38M |
| Sep 23, 2026 | 44.41 | 44.41 | 39.82 | 41.05 | 2.61M |
| Sep 22, 2026 | 44.99 | 45.99 | 44.39 | 44.51 | 2.09M |
| Sep 21, 2026 | 45.70 | 45.98 | 44.09 | 44.64 | 1.18M |
About Edgewise Therapeutics
Edgewise Therapeutics (EWTX) is listed on the Nasdaq and classified by the SEC under βPharmaceutical Preparationsβ. Its business address is in BOULDER, CO. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1710072.
EWTX board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Laura Brege | Director | Jun 17, 2026 |
| Badreddin Edris | Director | Jun 16, 2026 |
| Jonathan C Fox | Director | Jul 1, 2026 |
| Kevin Koch | President and CEO | Aug 14, 2026 |
| Christopher Nathan Martin | Director | Jun 16, 2026 |
| Arlene Morris | Director | Jun 17, 2026 |
| Jonathan D Root | Director | Jul 17, 2026 |
| Alan J Russell | Chief Scientific Officer | Aug 17, 2026 |
| Peter A. Thompson | Director | Jun 17, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Behrad Derakhshan | Chief Business Officer | Aug 17, 2026 |
| Joanne M. Donovan | CMO | Aug 17, 2026 |
| Kevin Koch | President and CEO | Aug 14, 2026 |
| John R Moore | General Counsel | Aug 17, 2026 |
| Michael Nofi | Chief Financial Officer | Aug 17, 2026 |
| Alan J Russell | Chief Scientific Officer | Aug 17, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 13, 2026 | Joanne M. Donovan | Sale | 2,919 | $43.41 |
| Aug 13, 2026 | Joanne M. Donovan | Sale | 2,919 | $43.41 |
| Aug 13, 2026 | Joanne M. Donovan | Sale | 2,919 | $43.41 |
| Aug 13, 2026 | Joanne M. Donovan | Sale | 2,919 | $43.41 |
| Aug 12, 2026 | Joanne M. Donovan | Sale | 800 | $44.52 |
| Aug 12, 2026 | Joanne M. Donovan | Sale | 104 | $44.43 |
| Aug 12, 2026 | Joanne M. Donovan | Sale | 2,779 | $43.71 |
| Aug 12, 2026 | Joanne M. Donovan | Sale | 2,839 | $43.78 |
| Aug 12, 2026 | Joanne M. Donovan | Sale | 800 | $44.52 |
| Aug 12, 2026 | Joanne M. Donovan | Sale | 104 | $44.43 |
| Aug 12, 2026 | Joanne M. Donovan | Sale | 2,779 | $43.71 |
| Aug 12, 2026 | Joanne M. Donovan | Sale | 2,839 | $43.78 |
| Aug 12, 2026 | Joanne M. Donovan | Sale | 800 | $44.52 |
| Aug 12, 2026 | Joanne M. Donovan | Sale | 104 | $44.43 |
| Aug 12, 2026 | Joanne M. Donovan | Sale | 2,779 | $43.71 |
EWTX financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | β | $-167.79M | -1.63 | $-143.82M |
| Dec 31, 2024 | β | $-133.81M | -1.45 | $-109.03M |
| Dec 31, 2023 | β | $-100.16M | -1.57 | $-91.95M |
| Dec 31, 2022 | β | $-67.64M | -1.26 | $-52.63M |
| Dec 31, 2021 | β | $-42.81M | -1.14 | $-33.51M |
Latest balance sheet: total assets $479.69M, total liabilities $31.61M, cash $72.32M (as of Jun 30, 2026).
EWTX earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $44.42 |
| May 7, 2026 | 8-K Item 2.02 (results) | $35.58 |
| Feb 26, 2026 | 8-K Item 2.02 (results) | $29.66 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $17.09 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $12.95 |
| May 8, 2025 | 8-K Item 2.02 (results) | $14.70 |
| Mar 3, 2025 | 8-K Item 2.02 (results) | $25.53 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $35.43 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | β |
| May 9, 2024 | 8-K Item 2.02 (results) | β |
| Feb 22, 2024 | 8-K Item 2.02 (results) | β |
| Jan 19, 2024 | 8-K Item 2.02 (results) | β |
Related stocks Β· Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on EWTX
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.